Further efforts are being focused on the discovery of novel coumarin-based anti-breast cancer agents dual targeting the estrogen receptors (ER) and vascular endothelial growth factor receptor-2 (VEGFR-2). This evidence concerns the gene ESR1 and breast cancer.